CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $455,296 | +38.5% | 8,110 | +11.6% | 0.07% | +17.5% |
| Q1 2023 | $328,687 | +91.7% | 7,267 | +72.3% | 0.06% | +80.0% |
| Q4 2022 | $171,421 | +236.1% | 4,217 | +439.3% | 0.04% | +191.7% |
| Q3 2022 | $51,000 | +64.5% | 782 | +51.6% | 0.01% | +71.4% |
| Q2 2022 | $31,000 | -16.2% | 516 | -11.9% | 0.01% | 0.0% |
| Q1 2022 | $37,000 | +27.6% | 586 | +53.8% | 0.01% | +16.7% |
| Q4 2021 | $29,000 | +2800.0% | 381 | +6250.0% | 0.01% | – |
| Q3 2021 | $1,000 | 0.0% | 6 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | – | 6 | +50.0% | 0.00% | – |
| Q1 2021 | $0 | -100.0% | 4 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | – | 4 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |